Medications and CGM Coverage Guide: 2023 Q1 Edition
Last updated 03/14/2023
Quickly reference insurance plan coverage in this all-in-one guide for your patients with type 2 diabetes.
Medications and devices referenced include:
SGLT-2 Inhibitors
Jardiance, Farxiga, Invokana, Steglatro
GLP1-Receptor Agonists / GIPs
Trulicity, Ozempic, Victoza, Rybelsus, Bydureon BCise, Mounjaro
Anti-Obesity Medications
Saxenda, Wegovy, phentermine, Lomaira, Qsymia, Contrave
Continuous glucose monitors (CGMs)
Device brands preferred by each payor
Plans include major commercial plans/PBMs in Michigan (Aetna, BCBSM, Express Scripts, HAP, Priority Traditional, Priority Optimized, and United), as well as Medicare, Medicare Advantage plans (Aetna, BCBSM/BCN, HAP, Humana, Priority, United, and Wellcare), and Michigan Medicaid.
Developed by the Michigan Collaborative for Type 2 Diabetes.
Tags:
For ProvidersNon-videoPDFMedicareCreated-By-MCT2DPoint-of-careCoverage